Entera Bio presented preclinical data for OPK-8801003, showing a longer half-life and peak plasma levels similar to Gattex®, the only approved GLP-2 therapy. This oral GLP-2 tablet could revolutionize treatment for 30,000 Short Bowel Syndrome patients who currently rely on daily injections. The data, presented at ESPEN, revealed the extended half-life of 15 hours, peak plasma concentrations exceeding teduglutide, sustained exposure for over 24 hours, and a favorable safety profile. Short Bowel Syndrome affects 30,000 patients in the U.S. and EU, highlighting the potential impact of this new therapy.

Read more at GlobeNewswire: Entera Bio Reports Positive PK Data for First-in-Class Oral